Physician profile
Stanley Wayne Smith
NPI 1396729463
$5,885.81
in general payments reported to CMS, 2019-2025
46 companies · $1,122 in 2025
The $1,122 reported for 2025 was more than what 95% of Hospitalist providers received nationally (typical 2025 total: $85.87).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $762 · 2020: $451 · 2021: $476 · 2022: $930 · 2023: $926 · 2024: $1,219 · 2025: $1,122.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,267.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,267.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $658.07 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $534.47 | 2019-2025 | Jardiance, Synjardy, Tradjenta |
| Abbvie INC. | $479.34 | 2019-2025 | Ubrelvy, Qulipta, Synthroid |
| Novo Nordisk INC | $477.83 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Astellas Pharma US INC | $356.28 | 2019-2025 | Veozah |
| Glaxosmithkline, LLC. | $337.13 | 2019-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Lilly USA, LLC | $336.11 | 2022-2025 | Mounjaro, Zepbound, Trulicity |
| Sanofi-Aventis U.S. LLC | $320.85 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $204.42 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $193.39 | 2019-2025 | Spravato |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $191.92 | 2021-2025 | Xifaxan |
| Pfizer INC. | $189.61 | 2019-2025 | |
| Amgen INC. | $162.34 | 2019-2024 | Repatha, Otezla |
| Otsuka America Pharmaceutical, INC. | $121.18 | 2023-2025 | Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $120.81 | 2020-2022 |
Show all 46 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stanley Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.